Award Received
July 2022
ExoMira receives NIH/NIAID funded RO1 sub award with Northwestern University.
Previous
Previous
New Headquarter
Next
Next
July 2022
ExoMira receives NIH/NIAID funded RO1 sub award with Northwestern University.
ExoMira Medicine Inc. (“ExoMira”) is a Chicago-based preclinical-stage pharmaceutical company (a spin-off from Northwestern University) focused on developing innovative cancer immunotherapies.